ALPHA-INTERFERON THERAPY FOR SEVERE CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDREN

We report the use of alpha2b-interferon in 15 children with symptomati c, chronic idiopathic thrombocytopenic purpura, who did not respond to standard therapy. The platelet count increased in nine children durin g therapy. In six children the increase lasted less than 6 weeks. An i ncreased platelet count was seen when a higher dose was used in two of four initial nonresponders. One responder who relapsed had an identic al response when retreated with the same dose. No significant side eff ects were documented. Further studies are required to establish the op timal dose and administration schedule of alpha2b-interferon for use i n children with chronic idiopathic thrombocytopenic purpura. (C) Wiley -Liss, Inc.